Commercial Launch Project Manager (CONTRACT)
Summit Therapeutics
| Company | Summit Therapeutics |
| Category | Uncategorised |
| Location | Princeton |
| Remote | On-site (inferred) |
| Employment | Not stated |
| Level | Not stated |
| Salary | Not stated by the employer |
| Posted | 30 Jul 2026 |
| Last verified | 2 Aug 2026 |
| Source | Employer ATS (greenhouse) |
Description
About Summit:
Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit’s core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence.
Summit’s team is inspired to touch and help change lives through Summit’s clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including:
Non-small Cell Lung Cancer (NSCLC)
HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI.
HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC.
HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC.
Colorectal Cancer (CRC)
HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy.
Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, and has additional offices in California, New Jersey, the UK, and Ireland.
Overview of Role:
The Commercial Launch Project Manager will optimize , embed, and continuously evolving Summit Therapeutics launch execution and project management capability.
This role will serve as an operational partner for the Commercial launch team. The role also includes working and collaborating with project managers supporting Medical Affairs, CMC , and various cross-functional partners .
Role and Responsibilities:
Support commercial team launch planning and execution for launch readiness of various sub team/s including Marketing and Market Research, Commercial Operations, Analytics, Sales, Market Access, Forecasting, and other functions as appropriate.
Collaborate with Medical and CMC launch project managers and key partner functions to build integrated launch overview for new product launches, indication expansions, and lifecycle management.
Establish and maintain dashboards, KPIs, and governance frameworks to monitor progress, identify risks and develop mitigation solutions, and drive accountability for the entire launch team.
Facilitate strategic reviews, cross-functional planning meetings, and business reviews.
Coordinate the planning and tracking of governance structure and meetings including, Promotional Review Committee (PRC), internal leadership meetings to support launch readiness.
Support operational scalability by implementing cross-functional processes, systems, and governance frameworks across launch ecosystem.
Contribute to the development of robust p